The CNAG-CRG participates in a European project to improve medical assistance through interceptive medicine
Scientists from the Centro Nacional de Análisis Genómico (CNAG-CRG), based in Barcelona Science Park and integrated to the Centre for Genomic Regulation (CRG) unites with hundreds of innovators, research pioneers, clinicians, industry leaders and policy makers from all around Europe are united to revolutionize healthcare on the frame of LifeTime initiative. They are participating in two publications: a perspective article in the journal Nature and the LifeTime Strategic Research Agenda. They are now presenting how to improve leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual’s lifetime.
The LifeTime initiative, including the Centre for Genomic Regulation (CRG) and the Centro Nacional de Análisis Genómico (CNAG-CRG), based in Barcelona, has developed a strategy to advance personalised treatment for cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases. The aim is a new age of personalised, cell-based interceptive medicine for Europe with the potential of improved health outcomes and more cost-effective treatment, resulting in profoundly changing a person’s healthcare experience.
Using breakthrough single-cell and imaging technologies in combination with artificial intelligence and personalized disease models will allow us to not only predict disease onset earlier, but also to select the most effective therapies for individual patients. Targeting disease-causing cells to intercept disorders before irreparable damage occurs will substantially improve the outlook for many patients and has the potential of saving billions of Euros of disease-related costs in Europe.
The perspective article “LifeTime and improving European healthcare through cell-based interceptive medicine” and the LifeTime Strategic Research Agenda (SRA) explain how these technologies should be rapidly co-developed, transitioned into clinical settings and applied to the five major disease areas. Close interactions between European infrastructures, research institutions, hospitals and industry will be essential to generate, share and analyse LifeTime’s big medical data across European borders. The initiative’s vision advocates ethically responsible research to benefit citizens all across Europe.
More information at CRG’s website [+]